<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947866</url>
  </required_header>
  <id_info>
    <org_study_id>2019-SMEZ-EL-103</org_study_id>
    <nct_id>NCT03947866</nct_id>
  </id_info>
  <brief_title>Ezetimibe-Simvastatin Evaluation Study</brief_title>
  <acronym>ZEUS</acronym>
  <official_title>Non-interventional, Multicenter, Clinical Observational Study to Evaluate the Efficacy of a Fixed Combination of Ezetimibe and Simvastatin in Hypercholesterolemic Patients Not Responding to Statin Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elpen Pharmaceutical Co. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elpen Pharmaceutical Co. Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to assess the efficacy of the fixed combination of ezetimibe-simvastatin
      in patients with hypercholesterolemia not responding to statin monotherapy in achieving the
      blood plasma LDL-C target as defined by the ESC / EAS Guideline, of 2016.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The additional study objectives are:

        1. To evaluate the efficacy of a fixed combination of ezetimibe-simvastatin in patients
           with hypercholesterolemia to improve the lipid profile (HDL-C ↑, T-CHOL, Triglycerides
           ↓).

        2. Evaluation of the response of patients with hypercholesterolemia who received a fixed
           combination of ezetimibe-simvastatin to achieve a target according to the category of
           total cardiovascular risk to which they belong.

        3. To evaluate the efficacy of a stable combination of ezetimibe and simvastatin in
           patients with hypercholesterolemia in improving non-HDL-cholesterol (non-HDL-C) levels.

        4. Safety assessment through the recording of Adverse Events during the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>3 months</time_frame>
    <description>Levels of LDL-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipidemic profile</measure>
    <time_frame>3 months</time_frame>
    <description>HDL-C↑ T-CHOL, Triglycerides measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factor</measure>
    <time_frame>3 months</time_frame>
    <description>Response of patients vs target of total cardiovascular risk to which they belong.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Adverse Events during the study.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipidemias</condition>
  <condition>Statin Monotherapy Response</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hyperlcholesterolaemia - not responders to statin monotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with primary (heterozygous familial and non-familial)
             hypercholesterolemia, homozygous familial hypercholesterolemia or mixed
             hyperlipidemia.

          -  Patients not properly responded with a statin only.

          -  Patients who have not achieved LDL-C with previous treatment.

          -  Adult patients who will sign their consent form to participate in the study.

        Exclusion Criteria:

          -  Patients who have not fully understood the study procedures and have not signed the
             consent form.

          -  Hypersensitivity to the active substances or to any of the excipients of study drug.

          -  Pregnancy and breastfeeding.

          -  Active liver disease or unexplained persistent increases in serum transaminases.

          -  Concomitant administration of potent inhibitors of the CYP3A4 system (agents that
             increase the AUC approximately 5 times or more) (eg, itraconazole, ketoconazole,
             posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease
             inhibitors (eg nelfinavir ), boceprevir, telaprevir, nefazodone and combesistate
             containing medicines.

          -  Concomitant administration of gemfibrozil, cyclosporine or danazol.

          -  Patients with homozygous familial hypercholesterolaemia (HoFH), concurrent
             administration of lopithipid with doses of study drug&gt; 10 mg / 40 mg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegría E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs RH, Kjekshus JK, Perrone Filardi P, Riccardi G, Storey RF, David W; Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. [ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol. 2011 Dec;64(12):1168.e1-1168.e60. doi: 10.1016/j.recesp.2011.09.014. Review. Spanish.</citation>
    <PMID>22115524</PMID>
  </reference>
  <reference>
    <citation>Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.</citation>
    <PMID>27567407</PMID>
  </reference>
  <reference>
    <citation>M. Elisaf, Chr. Pitsavos, Ev. Liberopoulos, K. Tziomalos, V. Athyros. Updated guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia. Hellenic Journal of Atherosclerosis (2014) 5: 151-163</citation>
  </reference>
  <reference>
    <citation>D. B. Panagiotakos. Cardiovascular Disease Risk Models. Hellenic Journal of Atherosclerosis (2013) 4: 151-157</citation>
  </reference>
  <reference>
    <citation>Panagiotakos DB, Fitzgerald AP, Pitsavos C, Pipilis A, Graham I, Stefanadis C. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J Cardiol. 2007 Mar-Apr;48(2):55-63.</citation>
    <PMID>17489342</PMID>
  </reference>
  <reference>
    <citation>Walker JF. Simvastatin: the clinical profile. Am J Med. 1989 Oct 16;87(4A):44S-46S.</citation>
    <PMID>2801750</PMID>
  </reference>
  <reference>
    <citation>Simons LA. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators. Clin Cardiol. 1993 Apr;16(4):317-22.</citation>
    <PMID>8458112</PMID>
  </reference>
  <reference>
    <citation>Rabelink AJ, Hené RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet. 1988 Dec 10;2(8624):1335-8.</citation>
    <PMID>2904053</PMID>
  </reference>
  <reference>
    <citation>Shankar PK, Bhat R, Prabhu M, Reddy BP, Reddy MS, Reddy M. Efficacy and tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with primary hypercholesterolemia: Results of a multicentric trial from India. J Clin Lipidol. 2007 Aug;1(4):264-70. doi: 10.1016/j.jacl.2007.07.009. Epub 2007 Jul 27.</citation>
    <PMID>21291690</PMID>
  </reference>
  <reference>
    <citation>Nußbaumer B, Glechner A, Kaminski-Hartenthaler A, Mahlknecht P, Gartlehner G. Ezetimibe-Statin Combination Therapy. Dtsch Arztebl Int. 2016 Jul 1;113(26):445-53. doi: 10.3238/arztebl.2016.0445.</citation>
    <PMID>27412989</PMID>
  </reference>
  <reference>
    <citation>Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007 Aug;23(8):2009-26.</citation>
    <PMID>17659159</PMID>
  </reference>
  <reference>
    <citation>Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest. 2007 May;37(5):357-63.</citation>
    <PMID>17461981</PMID>
  </reference>
  <reference>
    <citation>Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18;40(12):2125-34.</citation>
    <PMID>12505224</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.</citation>
    <PMID>26039521</PMID>
  </reference>
  <reference>
    <citation>M.Elisaf, A.Kei, T.Alexandrides, E. Liberopoulos. The impact of improve-it study. Hellenic Journal of Atherosclerosis 6: 153-154</citation>
  </reference>
  <reference>
    <citation>Ahmed O, Littmann K, Gustafsson U, Pramfalk C, Öörni K, Larsson L, Minniti ME, Sahlin S, Camejo G, Parini P, Eriksson M. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. J Am Heart Assoc. 2018 Dec 18;7(24):e009876. doi: 10.1161/JAHA.118.009876.</citation>
    <PMID>30561264</PMID>
  </reference>
  <reference>
    <citation>Bove M, Fogacci F, Cicero AFG. Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1099-1104. doi: 10.1080/17425255.2017.1381085. Epub 2017 Sep 26. Review.</citation>
    <PMID>28922021</PMID>
  </reference>
  <reference>
    <citation>Abramson J, Rosenberg HG, Jewell N, Wright JM. Safety and efficacy of statins. Lancet. 2017 Mar 18;389(10074):1097. doi: 10.1016/S0140-6736(17)30713-4.</citation>
    <PMID>28322813</PMID>
  </reference>
  <reference>
    <citation>Robinson JG. Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia. Prog Cardiovasc Dis. 2016 Sep - Oct;59(2):165-171. doi: 10.1016/j.pcad.2016.07.011. Epub 2016 Aug 4. Review.</citation>
    <PMID>27498088</PMID>
  </reference>
  <reference>
    <citation>Kei A, Elisaf MS. Nicotinic acid: clinical considerations. Expert Opin Drug Saf. 2012 Jul;11(4):551-64. doi: 10.1517/14740338.2012.682981. Epub 2012 May 7. Review.</citation>
    <PMID>22564238</PMID>
  </reference>
  <reference>
    <citation>A. Kei, M.Elisaf. Current role of fibrates in the treatment of dyslipidemia. Hellenic Journal of Atherosclerosis 5(2): 106-11</citation>
  </reference>
  <reference>
    <citation>Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 19;136(25):2440-2450. doi: 10.1161/CIRCULATIONAHA.117.029095. Epub 2017 Sep 30.</citation>
    <PMID>28972004</PMID>
  </reference>
  <reference>
    <citation>Ghanim H, Green K, Abuaysheh S, Patel R, Batra M, Chaudhuri A, Makdissi A, Kuhadiya ND, Dandona P. Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. Atherosclerosis. 2017 Aug;263:278-286. doi: 10.1016/j.atherosclerosis.2017.06.010. Epub 2017 Jun 7.</citation>
    <PMID>28711708</PMID>
  </reference>
  <reference>
    <citation>Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992 Jan-Mar;2(1-2):23-8.</citation>
    <PMID>1342260</PMID>
  </reference>
  <reference>
    <citation>Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 4;104(10):1108-13.</citation>
    <PMID>11535564</PMID>
  </reference>
  <reference>
    <citation>Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003.</citation>
    <PMID>12788299</PMID>
  </reference>
  <reference>
    <citation>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.</citation>
    <PMID>11368702</PMID>
  </reference>
  <reference>
    <citation>Suchy D, Łabuzek K, Stadnicki A, Okopień B. Ezetimibe--a new approach in hypercholesterolemia management. Pharmacol Rep. 2011;63(6):1335-48. Review.</citation>
    <PMID>22358082</PMID>
  </reference>
  <reference>
    <citation>Al-Shaer MH, Choueiri NE, Suleiman ES. The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Lipids Health Dis. 2004 Oct 7;3:22.</citation>
    <PMID>15471540</PMID>
  </reference>
  <reference>
    <citation>Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets. 2006 Dec;10(6):851-66. Review.</citation>
    <PMID>17105372</PMID>
  </reference>
  <reference>
    <citation>Jankowski P, Loster M, Kawecka-Jaszcz K. Ezetimibe: New perspectives in lipid lowering treatment. Cardiol J. 2007;14(3):232-7.</citation>
    <PMID>18651466</PMID>
  </reference>
  <reference>
    <citation>Kostapanos MS, Mikhailidis DP, Elisaf MS. Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit? Future Cardiol. 2012 Nov;8(6):813-7. doi: 10.2217/fca.12.64.</citation>
    <PMID>23176685</PMID>
  </reference>
  <reference>
    <citation>Kostapanos MS, Elisaf MS, Mikhailidis DP. Ezetimibe - a new approach in hypercholesterolemia management. Pharmacol Rep. 2012;64(4):997-8.</citation>
    <PMID>23087154</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

